Sarfaraz K. Niazi
Handbook of Pharmaceutical Manufacturing Formulations, Third Edition (eBook, ePUB)
Volume Four, Semisolid Products
48,95 €
48,95 €
inkl. MwSt.
Sofort per Download lieferbar
48,95 €
Als Download kaufen
48,95 €
inkl. MwSt.
Sofort per Download lieferbar
Sarfaraz K. Niazi
Handbook of Pharmaceutical Manufacturing Formulations, Third Edition (eBook, ePUB)
Volume Four, Semisolid Products
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
The Handbook of Pharmaceutical Manufacturing Formulations, Third Edition: Volume Four, Semisolid Products is an authoritative and practical guide to the art and science of formulating drugs for commercial manufacturing.
- Geräte: eReader
- ohne Kopierschutz
- eBook Hilfe
- Größe: 7.99MB
The Handbook of Pharmaceutical Manufacturing Formulations, Third Edition: Volume Four, Semisolid Products is an authoritative and practical guide to the art and science of formulating drugs for commercial manufacturing.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 502
- Erscheinungstermin: 6. Dezember 2019
- Englisch
- ISBN-13: 9781351593328
- Artikelnr.: 58386673
- Verlag: Taylor & Francis
- Seitenzahl: 502
- Erscheinungstermin: 6. Dezember 2019
- Englisch
- ISBN-13: 9781351593328
- Artikelnr.: 58386673
Sarfaraz K. Niazi, Ph.D., a well-recognized authority on drug and dosage form development including biological drugs and alternative medicines. He is Founder and Executive Chairman of Adello Biologics, LLC, (formerly, Therapeutic Proteins International, LLC), a biosimilar products company located in Chicago, IL, Piscataway, NJ and Cashel, Ireland. As an entrepreneur, Niazi has raised hundreds of millions of dollars and became recognized as an inductee into the Chicago Entrepreneur Hall of Fame.Niazi began his career teaching pharmaceutical sciences at the University of Illinois, College of Pharmacy where he was tenured before entering the industry at Abbott International. He departed Abbott as an Abbott Volwiler Fellow to pursue his passion, first through global consulting and later through the founding a biosimilar products company.
A prolific inventor with scores of patents, most prominently in the field of bioprocessing technology, Niazi is currently the largest single holder of bioprocess technology patents. His other inventions span a broad category of technologies, new chemical entities, new formulations, new analytical methodologies, and much more. He has hands on experience in developing chemical, botanical and biological products, from discovery to regulatory approval. With over 50 ISBNs under his name, Niazi has authored many landmark books in the field of pharmaceutical sciences.
He currently serves as Adjunct Professor at the University of Illinois College of Pharmacy, Ad Hoc faculty at the University of Houston, Texas, the HEJ Research Institute, Karachi, and the National University of Science and Technology, Islamabad. He has also served as a Foreign Professor at the HEJ Research Institute, Karachi. He serves on the editorial board of the journal MOJ Proteomics & Bioinformatics (MOJPB) and starting 2017, as Chief Editor of International Journal of Biosimilars. He also serves as Member of National Advisory Board of the College of Pharmacy, University of Illinois. He is a Fellow of the Pakistan Academy of Medical Sciences, Fellow National Academy of Clinical Biochemistry and Institute of Biology. He served as a TOKTEN Fellow to India (Transfer of Knowledge Through Expatriate Nationals (UNDP). In 2013, he received the one of the highest civilian awards, Star of Distinction in Engineering, from the Pakistani President. He has hosted a radio show at Voice of America (US State Department) on a weekly basis for more than 5 years with audience into billions.
A prolific inventor with scores of patents, most prominently in the field of bioprocessing technology, Niazi is currently the largest single holder of bioprocess technology patents. His other inventions span a broad category of technologies, new chemical entities, new formulations, new analytical methodologies, and much more. He has hands on experience in developing chemical, botanical and biological products, from discovery to regulatory approval. With over 50 ISBNs under his name, Niazi has authored many landmark books in the field of pharmaceutical sciences.
He currently serves as Adjunct Professor at the University of Illinois College of Pharmacy, Ad Hoc faculty at the University of Houston, Texas, the HEJ Research Institute, Karachi, and the National University of Science and Technology, Islamabad. He has also served as a Foreign Professor at the HEJ Research Institute, Karachi. He serves on the editorial board of the journal MOJ Proteomics & Bioinformatics (MOJPB) and starting 2017, as Chief Editor of International Journal of Biosimilars. He also serves as Member of National Advisory Board of the College of Pharmacy, University of Illinois. He is a Fellow of the Pakistan Academy of Medical Sciences, Fellow National Academy of Clinical Biochemistry and Institute of Biology. He served as a TOKTEN Fellow to India (Transfer of Knowledge Through Expatriate Nationals (UNDP). In 2013, he received the one of the highest civilian awards, Star of Distinction in Engineering, from the Pakistani President. He has hosted a radio show at Voice of America (US State Department) on a weekly basis for more than 5 years with audience into billions.
Part I Regulatory and Manufacturing Guidance
Chapter 1. Waiver of In Vivo Bioequivalence Study
Chapter 2. Quality Risk Management
Chapter 3. Pharmaceutical Quality System
Chapter 4. Pharmaceutical Development
Chapter 5. Scale-Up and Postapproval Changes for Nonsterile Semisolid
Dosage Forms: Manufacturing Equipment
Chapter 6. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
Chapter 7. Validation of Analytical Procedures
Chapter 8. Bioequivalence Testing of Topical Drugs
Chapter 9. Active Pharmaceutical Ingredients: GMP Compliance and Inspection
Chapter 10. Test Procedures and Acceptance Criteria for New Chemical Drug
Substances and Drug Products
Chapter 11. Topical Testing of Transdermal Drug Products
Chapter 12. Impurities Profiling: Drug Substance
Chapter 13. Impurities in New Drug Products
Chapter 14. Formulation Factors in Semisolid Dosage Forms
Chapter 15. Pediatric Research Equity Act (PREA) Compliance
Chapter 16. Global Regulatory Guidance on Bioequivalence Testing
Chapter 17. Bioavailability and Bioequivalence Studies Submitted in NDAs or
INDs - General Considerations
Chapter 18. FDA 483 Observations
Chapter 19. WHO Good Manufacturing Guidelines
Appendices
Part II Manufacturing Formulations
Semisolid Formulations
Part III Commercial Pharmaceutical Formulations
Commercial Pharmaceutical Formulations
Chapter 1. Waiver of In Vivo Bioequivalence Study
Chapter 2. Quality Risk Management
Chapter 3. Pharmaceutical Quality System
Chapter 4. Pharmaceutical Development
Chapter 5. Scale-Up and Postapproval Changes for Nonsterile Semisolid
Dosage Forms: Manufacturing Equipment
Chapter 6. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
Chapter 7. Validation of Analytical Procedures
Chapter 8. Bioequivalence Testing of Topical Drugs
Chapter 9. Active Pharmaceutical Ingredients: GMP Compliance and Inspection
Chapter 10. Test Procedures and Acceptance Criteria for New Chemical Drug
Substances and Drug Products
Chapter 11. Topical Testing of Transdermal Drug Products
Chapter 12. Impurities Profiling: Drug Substance
Chapter 13. Impurities in New Drug Products
Chapter 14. Formulation Factors in Semisolid Dosage Forms
Chapter 15. Pediatric Research Equity Act (PREA) Compliance
Chapter 16. Global Regulatory Guidance on Bioequivalence Testing
Chapter 17. Bioavailability and Bioequivalence Studies Submitted in NDAs or
INDs - General Considerations
Chapter 18. FDA 483 Observations
Chapter 19. WHO Good Manufacturing Guidelines
Appendices
Part II Manufacturing Formulations
Semisolid Formulations
Part III Commercial Pharmaceutical Formulations
Commercial Pharmaceutical Formulations
Part I Regulatory and Manufacturing Guidance
Chapter 1. Waiver of In Vivo Bioequivalence Study
Chapter 2. Quality Risk Management
Chapter 3. Pharmaceutical Quality System
Chapter 4. Pharmaceutical Development
Chapter 5. Scale-Up and Postapproval Changes for Nonsterile Semisolid
Dosage Forms: Manufacturing Equipment
Chapter 6. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
Chapter 7. Validation of Analytical Procedures
Chapter 8. Bioequivalence Testing of Topical Drugs
Chapter 9. Active Pharmaceutical Ingredients: GMP Compliance and Inspection
Chapter 10. Test Procedures and Acceptance Criteria for New Chemical Drug
Substances and Drug Products
Chapter 11. Topical Testing of Transdermal Drug Products
Chapter 12. Impurities Profiling: Drug Substance
Chapter 13. Impurities in New Drug Products
Chapter 14. Formulation Factors in Semisolid Dosage Forms
Chapter 15. Pediatric Research Equity Act (PREA) Compliance
Chapter 16. Global Regulatory Guidance on Bioequivalence Testing
Chapter 17. Bioavailability and Bioequivalence Studies Submitted in NDAs or
INDs - General Considerations
Chapter 18. FDA 483 Observations
Chapter 19. WHO Good Manufacturing Guidelines
Appendices
Part II Manufacturing Formulations
Semisolid Formulations
Part III Commercial Pharmaceutical Formulations
Commercial Pharmaceutical Formulations
Chapter 1. Waiver of In Vivo Bioequivalence Study
Chapter 2. Quality Risk Management
Chapter 3. Pharmaceutical Quality System
Chapter 4. Pharmaceutical Development
Chapter 5. Scale-Up and Postapproval Changes for Nonsterile Semisolid
Dosage Forms: Manufacturing Equipment
Chapter 6. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients
Chapter 7. Validation of Analytical Procedures
Chapter 8. Bioequivalence Testing of Topical Drugs
Chapter 9. Active Pharmaceutical Ingredients: GMP Compliance and Inspection
Chapter 10. Test Procedures and Acceptance Criteria for New Chemical Drug
Substances and Drug Products
Chapter 11. Topical Testing of Transdermal Drug Products
Chapter 12. Impurities Profiling: Drug Substance
Chapter 13. Impurities in New Drug Products
Chapter 14. Formulation Factors in Semisolid Dosage Forms
Chapter 15. Pediatric Research Equity Act (PREA) Compliance
Chapter 16. Global Regulatory Guidance on Bioequivalence Testing
Chapter 17. Bioavailability and Bioequivalence Studies Submitted in NDAs or
INDs - General Considerations
Chapter 18. FDA 483 Observations
Chapter 19. WHO Good Manufacturing Guidelines
Appendices
Part II Manufacturing Formulations
Semisolid Formulations
Part III Commercial Pharmaceutical Formulations
Commercial Pharmaceutical Formulations